Lauren White - 14 Feb 2022 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Financial Officer
Signature
/s/ Jolie Siegel, as Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
14 Feb 2022
Net transactions value
$0
Form type
4
Filing time
16 Feb 2022, 15:30:40 UTC
Previous filing
21 Jun 2021
Next filing
27 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 14 Feb 2022 Common Stock 100,000 $22.71 Direct F1
transaction CCCC Performance Restricted Stock Units Award $0 +26,250 $0.000000 26,250 14 Feb 2022 Common Stock 26,250 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2022.
F2 Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining 21,750 PRSUs shall vest upon satisfaction of certain discovery and clinical milestones.